Cite
MLA Citation
Alan Menter et al.. “Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.” Expert opinion on biological therapy, vol. 21, 2021, pp. 87–96. http://access.bl.uk/ark:/81055/vdc_100118546619.0x00001a